Clinical trials: Intravenous
Heart Failure, Congestive
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
The purpose of this study is to evaluate the efficacy of a 24-hour infusion of levosimendan compared with placebo in the treatment of decompensated chronic heart failure.
- Trial name
- NCT00048425
- Testing
- Levosimendan
- Where
- 166 sites in United States, Australia and 2 more
- Volunteers
- 600 people
- Sponsor
- Abbott
Healthy Volunteers
SAD and MAD Study With IV and SC Doses of ARGX-117
This is a phase 1, first-in-human, double-blinded, randomized, placebo-controlled, escalating single and multiple dose levels trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ARGX-117…
- Trial name
- ARGX-117 (NCT04532125)
- Testing
- ARGX-117, ARGX-117 + rHuPH20, ARGX-117 PH20 SC
- Where
- Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- argenx
Healthy Adults
Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan
This study is a single-center, randomized, open-label, active and placebo-controlled, parallel-group, conducted in healthy male volunteers who have been shown to be extensive metabolizers of dextromethorphan.
- Trial name
- NCT01367535
- Testing
- SC Methylnaltrexone (MNTX), IV Methylnaltrexone (MNTX), Oral Paroxetine
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Focal Liver Lesions
Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging
Liver tumours, 40% of which are benign, account for 1% to 4% of all solid tumours in children. The benign tumours are mainly haemangiomas, liver hamartomas, and liver cell adenomas.
- Trial name
- NCT06639828
- Testing
- Contrast-Enhanced Ultrasound
- Where
- 6 sites in Germany, Italy and 1 more
- Volunteers
- 50 people
- Sponsor
- GE Healthcare
Coronary Artery Disease, General Anesthetic Drug Allergy
Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery
Xenon is a gaseous anaesthetic agent registered in several European countries. It has been administered safely during cardiac surgery in pilot studies.
- Conditions
- Coronary Artery Disease, General Anesthetic Drug Allergy, Coronary Artery Bypass Graft Surgery
- Trial name
- NCT01294163
- Testing
- Xenon, Sevoflurane, Propofol
- Where
- 17 sites in France, Germany and 2 more
- Volunteers
- 509 people
- Sponsor
- Air Liquide Santé International
Sepsis, Coagulopathy
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
Researchers are looking for a better way to treat people who have sepsis induced coagulopathy. Sepsis happens when bacteria and their toxins spread in the blood, causing an infection.
- Trial name
- NCT06854640
- Testing
- BAY3389934
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 36 people
- Sponsor
- Bayer
Hemophilia A
Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
Primary objective To assess the half-life of BIVV001, Standard Half-Life (SHL) rFVIII and Extended Half-Life (EHL) rFVIII after a single intravenous (IV) injection Secondary objectives To characterize additional pharmacokinetic…
- Trial name
- NCT05042440
- Testing
- Efanesoctocog alfa, Octocog alfa, Rurioctocog alfa pegol
- Where
- Bulgaria
- Volunteers
- 13 people
- Sponsor
- Sanofi
Healthy Male Chinese Volunteers
A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects
The purpose of this study is to assess the bioequivalence of a 200 mg single dose Lacosamide (LCM) intravenous (iv) solution with a 200 mg single dose LCM oral tablet in healthy Chinese male subjects.
- Trial name
- NCT03204474
- Testing
- Lacosamide (LCM) tablet, Lacosamide (LCM) solution for infusion
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Multiple Myeloma
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Study for the outcome and safety of individualized busulfan dosing with bortezomib for patients preparing for a second stem cell transplant to treat multiple myeloma.
- Trial name
- NCT01009840
- Testing
- IV busulfan, bortezomib, Autologous Hematopoietic Stem Cell Transplant (HSCT)
- Where
- 13 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Arthritis, Rheumatoid
Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis
This is a randomized, double-blinded, placebo-controlled adaptive, dose finding study to investigate the safety, tolerability, PK, PD and efficacy of single and repeat intravenous infusions of GSK315243A in patients with active…
- Trial name
- NCT00674635
- Testing
- GSK3152314A
- Where
- 19 sites in Australia, New Zealand and 3 more
- Volunteers
- 135 people
- Sponsor
- GlaxoSmithKline
Endometrial Carcinoma, Neoplasms, Endometrial
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
This is an open-label study, meaning both the researchers and participants will know which treatment is being given. The study has two parts. In Part 1, researchers will identify the most suitable SC dose.
- Trial name
- SAPPHIRE (NCT07860450)
- Testing
- Dostarlimab, Carboplatin and paclitaxel
- Volunteers
- 378 people
- Sponsor
- GlaxoSmithKline
Middle Cerebral Artery Stroke
The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)
The safety and efficacy of MK0724 will be assessed in patients with acute middle cerebral artery stroke using the Action Reach Arm Test (ARAT).
- Trial name
- NCT00401310
- Testing
- Comparator: MK0724
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a single intravenous dose in subjects with major depressive disorder.
- Trial name
- NCT02067793
- Testing
- NRX-1074 1 mg, NRX-1074 5 mg, NRX-1074 10 mg
- Where
- 12 sites in United States
- Volunteers
- 151 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Colitis, Ulcerative
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics [PK]) in pediatric participants with…
- Trial name
- UNIFI Jr (NCT04630028)
- Testing
- Ustekinumab Dose Based on BSA and Body Weight
- Where
- 58 sites in United States, Belgium and 7 more
- Volunteers
- 112 people
- Sponsor
- Janssen Research & Development, LLC
Smoldering Multiple Myeloma
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
This study will assess the antimyeloma effects of BHQ880A in patients with smoldering multiple myeloma with high risk of progression to active multiple myeloma.
- Trial name
- NCT01302886
- Testing
- BHQ880
- Where
- 13 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Male Participants
A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881
The purpose of this Phase I, open-label study is to evaluate the absorption, distribution, metabolism, excretion, absolute bioavailability, and to characterize the metabolites of AG-881 in healthy male participants following…
- Trial name
- NCT03960502
- Testing
- AG-881, [13C315N3]AG-881
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Agios Pharmaceuticals, Inc.
Central Nervous System Pathology
Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Researchers in this study want to find the appropriate dose of drug BAY1747846 for adults undergoing MRI for known or highly suspected brain and/or spinal cord conditions so that the image quality is similar to that of drug…
- Trial name
- NCT04307186
- Testing
- Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist)
- Where
- 17 sites in United States, Bulgaria and 2 more
- Volunteers
- 57 people
- Sponsor
- Bayer
Tumors
A Phase I Study of G3139 Subcutaneous in Solid Tumors
Genasense® is currently administered to subjects in clinical studies as a multiple-day continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump that delivers the drug through a peripheral or…
- Trial name
- NCT00543231
- Testing
- G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Genta Incorporated
Lymphoma, Non-Hodgkin
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
The objective of the study (part A) is to evaluate the efficacy and safety of BAY80-6946 in patients with indolent or aggressive Non-Hodgkin's Lymphoma, who have progressed after standard therapy.
- Trial name
- NCT01660451
- Testing
- Copanlisib (Aliqopa, BAY80-6946)
- Where
- 102 sites in United States, Australia and 23 more
- Volunteers
- 227 people
- Sponsor
- Bayer
Solid Organ Tumors
An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors
First in human, open-label, sequential dose escalation and expansion study of intravenous BAL101553 in adult patients with advanced solid tumors.
- Trial name
- NCT01397929
- Testing
- BAL101553
- Where
- 3 sites in United Kingdom
- Volunteers
- 73 people
- Sponsor
- Basilea Pharmaceutica
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.